Abstract:Florenzo Iannone, 1 Fabrizio Conti, 2 Alberto Cauli, 3 Alberto Farina, 4 Roberto Caporali 5 1 Rheumatology Unit, Department of Emergency and Organ Transplantation, Università Degli Studi Di Bari Aldo Moro, Bari, Italy; 2 Rheumatology Unit, Department of Clinical, Internal, Anesthetic and Cardiovascular Sciences, Sapienza Università di Roma, Rome, Italy; 3 Rheumatology Unit, Department of Medical Sciences and Public Health, AOU and University of Cagliari, Monserrato, Italy; 4 Medical Affairs Department, Celltrion Healthcare Italy srl, Milan, Italy; 5 Department of Clinical Sciences and Community Health, Research Centre for Adult and Pediatric Rheumatic Diseases, University of Milan, Milan, Italy Correspondence: Florenzo Iannone, Rheumatology Unit, Department of Emergency and Organ Transplantation, Università Degli Studi Di Bari Aldo Moro, 11, Piazza Giulio Cesare, Bari (BA), 70124, Italy, Tel +39 080 5592775, Fax +39 080 5478802, Email The first subcutaneous (SC) formulation of infliximab CT-P13 has been authorized for the treatment of rheumatoid arthritis (RA) in Europe in 2019. Later, in 2020, approved indications were extended also to ankylosing spondylitis, psoriatic arthritis, psoriasis, Crohn's disease (CD) and ulcerative colitis (UC). The present review provides summary of the key features of SC infliximab, with particular focus on pharmacokinetic profile, clinical development program in comparison with the intravenous (IV) formulation, and the latest evidence in the literature. We conclude that SC infliximab represents a new and promising approach in the treatment of patients with RA, offering an optimized clinical profile and a more practical option in comparison to the IV formulation. Nevertheless, SC formulation can improve the use of national health systems resources (e.g., through the time of healthcare workers not having to supervise infusions) and facilitate social distancing measures during the COVID-19 pandemic, as the patient can self-inject the medicine at home without going to the hospital. The limitations of the SC infliximab are mainly due to the limited experience of use in clinical practice and the absence of long-term drug retention data. Keywords: rheumatoid arthritis, TNF inhibitors, infliximab, subcutaneous, intravenous, SC, IV, RA Rheumatoid arthritis (RA) is an immune mediated inflammatory disease affecting around 20 million people worldwide. 1 Symptoms are usually represented by joint pain, swelling and stiffness, which can lead to joint damage and irreversible disability. 2–5 RA patients, compared to general population, show higher rates of disability, and frequently have a reduced work productivity, as well as health-related quality of life (HRQoL). 6–8 The wide spread of the disease and the burden of its symptoms make RA a relevant global public health issue. Medical treatment, including drug therapy, is a well-established option in the management of RA, having its primary goal in sustained clinical remission of patients. Low disease activity can be considered an alternative target, in particular for patients with a long duration of illness. 9,10 European League Against Rheumatism (EULAR) recommends starting treatment with conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) early after diagnosis of RA. In case treatment target is not achieved with initial treatment with a csDMARD and poor prognostic factors are present, it is recommended to add a biologic DMARD (bDMARD) or a targeted synthetic DMARD (tsDMARDs). 9 bDMARDs include different classes depending on their mechanism of action. Among them, tumor necrosis factor (TNF) inhibitors were the first to enter clinical practice in the late 1990s and early 2000s, but still represent an effective and widely used option to switch disease activity off and halt structural joint damage. Currently authorized TNF inhibitors for the treatment of RA include adalimumab, certolizumab pegol, etanercept, golimumab, infliximab. This class was also the first to receive approval in Europe for a biosimilar medicine: infliximab in 2013. 11 In the same class, biosimilars of etanercept and adalimumab have been authorized since 2016 and 2017, respectively. 12,13 Overall, TNF inhibitors biosimilars contributed to make the use of this class more sustainable for national health systems and broaden access to therapy: in Italy, since their introduction in clinical practice in 2015, to 2020, the overall expenditure has reduced from 648M € to 347M €, and the number of Defined Daily Doses (DDD) administered per 1000 inhabitants per day has grown from 1.0 to 1.36. 14,15 Until the approval of the first subcutaneous (SC) formulation of infliximab in 201 -Abstract Truncated-

Rapid infusion of infliximab biosimilars and the incidence and severity of infusion-related reactions in patients with inflammatory bowel disease

Outcomes of the use of infliximab biosimilars in rheumatology and gastroenterology clinics

Fine comparision of the efficacy and safety between GB242 and infliximab in patients with active moderate to severe rheumatoid arthritis: a randomized, double-blind, phase III study

Drivers of infliximab biosimilar uptake: A comparative analysis of new biosimilar initiations versus switching in a national rheumatology registry

INFLIXIMAB MARKET SHARE AND ASSOCIATED COST SAVINGS FOLLOWING BIOSIMILAR MARKET ENTRY

Impact of Introducing Infliximab Biosimilars on Total Infliximab Consumption and Originator Infliximab Prices in Eight Regions: an Interrupted Time-Series Analysis

AB0192 COMPARABLE SAFETY AND EFFECTIVENESS AFTER TRANSITION TO A BIOSIMILAR ANTI-TNF IN INFLAMMATORY ARTHRITIS: POPULATION-BASED EVIDENCE FROM A POLICY CHANGE

Direct transition from rapid-infusion originator to rapid-infusion biosimilar tumor necrosis factor inhibitor in children with inflammatory bowel disease: A case series

A Randomized, Double‐Blind, Parallel Controlled, Single‐Dose Phase I Study Comparing the Pharmacokinetics, Safety, and Immunogenicity of the Infliximab Biosimilar CMAB008 and the Reference Product in Healthy Chinese Male Subjects

An Update on Anti-TNF Biosimilar Switching-Real-World Clinical Effectiveness and Safety

P885 Pharmacokinetics, pharmacodynamics, and immunogenicity of biosimilar infliximab in pediatric patients with inflammatory bowel disease

INFLIXIMAB AND ITS BIOSIMILARS FOR INFLAMMATORY BOWEL DISEASE: ANALYSIS OF MEDICARE PART D CLAIMS AND COSTS

Efficacy and safety of biosimilar versus originator infliximab in patients with inflammatory bowel disease: A real-world cohort analysis

Efficacy of Infliximab Biosimilar for Maintenance Therapy in Pediatric Inflammatory Bowel Disease Following Infliximab Originator

Multiple infliximab biosimilar switches appear to be safe and effective in a real-world inflammatory bowel disease cohort

P831 Acute infusion reactions due to different biologic agents in a large cohort of patients with Inflammatory Bowel Disease

P652 Transitioning Inflammatory Bowel Disease patients from an intravenous to a subcutaneous infliximab protocol: a single centre experience and patient satisfaction survey

MULTIPLE BIOSIMILAR INFLIXIMAB SWITCHING IS NOT ASSOCIATED WITH DISEASE FLARE IN INFLAMMATORY BOWEL DISEASE: A REAL-WORLD EFFECTIVENESS ANALYSES IN A NATIONAL U.S. COHORT

Subcutaneously-Administered Infliximab in the Management of Rheumatoid Arthritis: A Short Narrative Review of Current Clinical Evidence

P506. Predictors of Health-related Quality of Life in Asian Patients with Inflammatory Bowel Disease: Psychological, Clinical and Demographic Factors

Inpatient Infliximab Biosimilar Cost-Savings: Cost Analysis of Inpatient Treatment with Originator Infliximab (Remicade™) versus Biosimilar Infliximab (Renflexis™) for Acute Severe Ulcerative Colitis